What Is Happening With Thermo Fisher Scientific Stock?
Thermo Fisher Scientific (TMO)’s stock skyrocketed 50%, powered less by a modest 2% revenue rise and a slight dip in profit margin than by a soaring 48% jump in its P/E multiple. Behind this surge: consecutive earnings beats, bold acquisitions, and a fresh buyback plan—all hinting at renewed confidence and growth.
Below is an analytical breakdown of stock movement into key contributing metrics.
| 5252025 | 11212025 | Change | |
|---|---|---|---|
| Stock Price ($) | 392.9 | 587.5 | 49.5% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 42,898.0 | 43,735.0 | 2.0% |
| Net Income Margin (%) | 15.2% | 15.0% | -1.1% |
| P/E Multiple | 22.8 | 33.8 | 48.3% |
| Shares Outstanding (Mil) | 378.0 | 378.0 | 0.0% |
| Cumulative Contribution | 49.5% |
So what is happening here? The stock surged 50%, driven mainly by a 48% boost in its P/E multiple, while revenue edged up 2.0% and net margin dipped 1.1%. Let’s dive into the events behind these moves.
Here Is Why Thermo Fisher Scientific Stock Moved
- This Strategy Pays You 8.7% While Lining Up MPWR at Bargain Prices
- What Could Light a Fire Under Microsoft Stock
- 3 Key Risks That Could Drag Down Meta Platforms Stock
- Cash Machine Trading Cheap – Fiserv Stock Set to Run?
- Is Recursion Pharmaceuticals Stock Attractive?
- Comfort Systems USA Stock’s Winning Streak May Not Be Over Yet
- Q2 Earnings Beat: Q2 2025 revenue was $10.85B, adjusted EPS $5.36, exceeding estimates. Stock rose over 4% pre-market.
- Q3 Earnings Beat & Raise: Q3 2025 revenue $11.12B, adjusted EPS $5.79, beat estimates. 2025 guidance raised. Stock up ~2%.
- Solventum Acquisition: Acquired Solventum’s P&F business for $4B, boosting bioproduction, adding $750M revenue.
- Clario Holdings Acq.: To acquire Clario Holdings for $8.875B, expanding digital & AI in clinical research.
- Share Buyback Plan: Board approved a new $5.0 billion share repurchase program.
Our Current Assesment Of TMO Stock
Opinion: We currently find TMO stock unattractive. Why so? Have a look at the full story. Read Buy or Sell TMO Stock to see what drives our current opinion.
Risk: A good way to gauge risk with Thermo Fisher (TMO) is by checking how much it fell in major market sell-offs. It dropped about 41.5% in the Dot-Com crash and took an even bigger hit of around 54% during the Global Financial Crisis. The 2018 correction wasn’t as steep, but still a notable 17%. Covid led to a roughly 25% drop, and the inflation shock brought a 35% pullback. So even for a solid name like TMO, significant dips happen when markets turn sour. Quality helps, but it doesn’t make the stock immune to big sell-offs.
TMO stock may have seen strong gains recently, but investing in a single stock without detailed, thorough analysis can be risky. The Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 — the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.